Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya30651Editorial articleПередовая статьяCapacities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone systemВозможности лабораторной диагностики в оценке активности ренин-ангиотензин-альдостероновой системыMaksimovM LМаксимовМаксим Леонидович

Кафедра клинической фармакологии и пропедевтики внутренних болезней лечебного факультетаканд. мед. наук, доц; ГОУ ВПО ММА им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy

Кафедра клинической фармакологии и пропедевтики внутренних болезней лечебного факультетаканд. мед. наук, доц; ГОУ ВПО ММА им. И. М. Сеченова

maksim_maksimov@mail.ruI. M. Sechenov Moscow Medical AcademyГОУ ВПО ММА им. И. М. Сеченова15062010826NO6 (2010)ТОМ 82, №6 (2010)778109042020Copyright ©; 2010, Consilium MedicumCopyright ©; 2010, ООО "Консилиум Медикум"2010Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/30651

The renin-angiotensin-aldosterone system (RAAS) plays a substantial role in the regulation of many cardiovascular parameters and renal function, including the maintenance of blood pressure and water-salt exchange. The paper describes the most intensively used methods for determining the components of RAAS.

Ренин-ангиотензин-альдостероновая система (РААС) играет существенную роль в регуляции многих параметров сердечно-сосудистой системы и функции почек, включая поддержание артериального давления и водно-солевого обмена. В статье описываются наиболее активно используемые методы определения компонентов РААС.

renin-angiotensin-aldosterone systemreninangiotensin Iangiotensin IIaldosteroneplasma renin activityренин-ангиотензин-альдостероновая системаренинангиотензин Iангиотензин IIальдостеронактивность ренина плазмыBissessor N., White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc. Hlth Risk Manag. 2007; 3 (4): 425-430.Ortlepp J. R., Vosberg H. P., Reith S. et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002; 87 (3): 270-275.Griendling K. K., Murphy T. J., Alexander R. W. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.Funatsu H., Yamashita H., Nakanishi Y., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 2002; 86 (3): 311-315.Danser A. H. J., van den Dorpel M. A., Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. 1989; 68: 160-167.Deinum J., Derkx F. H. M., Danser A. H. J. et al. Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 1990; 126: 1673-1682.Sramek S. J., Wallow I. H. L., Tewksbury D. A. et al. An ocular renin-angiotensin system: immunohistochemistry of angiotensinogen. Invest. Ophthalmol. Vis. Sci. 1992; 33: 1627- 1632.Feman S. S., Mericle R. A., Reed G. W. et al. Serum angiotensin converting enzyme in diabetic patients. Am. J. Med. Sci. 1993; 305: 280-284.Danser A. H. J., Derkx F. H. M., Admiraal P. J. J. et al. Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1008-1018.Wagner J., Danser A. H. J., Derkx F. H. M. et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 1996; 80: 159-163.Амосова Е. Н. Клиническая кардиология. Киев: Здоров'я; 1998; т. 1.Дзяк Г. В., Васильева Л. И., Ханюков А. А. Артериальная гипертензия. Принципы и тактика лечения. Днепропетровск; 2000.Мареев В. Ю. Новые достижения в оптимизации лечения хронической сердечной недостаточности. Кардиология 1997; 12: 4-9.Campbell W. G. J., Ganhem F., Catanzaro D. F. et al. Plasma and renal prorenin/renin, renin mRNA and blood pressure in Dahl S and R rats. Hypertension 1996; 27: 1121-1133.Barajas L. Anatomy of the juxtaglomerular apparatus. Am. J. Physiol. 1979; 236 (5): F240-F246.Taugner R., Bührle C. P., Hackenthal E. et al. Morphology of the juxtaglomerular apparatus. Contrib. Nephrol. 1984; 43: 76-101.Kurtz A., Wagner Ch. Role of nitric oxide in the control of renin secretion. Am. J. Physiol. Renal Physiol. 1998; 275: F849-F862.Barajas L. Cell-specific protein and gene expression in the juxtaglomerular apparatus. Clin. Exp. Pharmacol. Physiol. 1997; 24: 520-526.Hall J. E. Historical perspective of the renin-angiotensin system. Mol. Biotechnol. 2003; 24: 27-39.Leyssac P. P., Holstein-Rathlou N. H., Skott O. Renal blood flow, early distal sodium, and plasma renin concentrations during osmotic diuresis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 279: R1268-R1276.Padmanabhan N., Padmanabhan S., Connell J. M. Genetic basis of cardiovascular disease - the renin-angiotensin-aldosterone system as a paradigm. J. Renin Angiotensin Aldosterone Syst. 2000; 1: 316-324.Hall J. E., Brands M. W., Shek E. W. Central role of the kidney and abnormal fluid volume control in hypertension. J. Hum. Hypertens. 1996; 10: 633-639.Skott O. Renin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282: R937-R939.Haber E. The role of renin in normal and pathological cardiovascular homeostasis. Circulation 1976; 54: 849-861.Kobori H., Nangaku M., Navar Q., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007; 59 (3): 251-287.Yiu W. H., Pan C. J., Ruef R. et al. The angiotensin system mediates renal fibrosis in glycogen storage disease type Ia nephropathy. Kidney Int. 2008; 73 (6): 716-723.Goodfriend T. J., Elliot M. E., Catt K. J. Angiotensin II receptors and their antagonists. N. Engl. J. Med. 1996; 334: 1649- 1654.Reilly C. F., Tewksbury D. A., Schechter N. M., Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J. Biol. Chem. 1982; 257: 861-862.Hollenberg N., Fisher N., Price D. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.Erdos E. G., Skidgel R. A. The angiotensin I-converting enzyme. Lab. Invest. 1987; 56: 345-348.Yang H. Y. T., Erdos E. G., Levin J. A dipeptidyl carboxypeptidase that converts angiotensin 1 and inactivates bradykinin. Biochim. Biophys. Acta 1970; 214: 374-376.Елисеева Ю. Е. Ангиотензинпревращающий фермент и его физиологическая роль. Вопр. мед. химии 2001; 47 (1): 43- 54.Li Q., Zhang J., Pfaffendorf M., van Zwieten P. A. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br. J. Pharmacol. 1995; 116: 2963-2970.Navar L. G., Inscho E. W., Majid S. A. et al. Paracrine regulation of the renal microcirculation. Physiol. Rev. 1996; 76: 525-536.Paul M., Mehr A. P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006; 86: 747-803.Timmermans P. B., Wong P. C., Chiu A. T. et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993; 45: 205-251.Navar L. G., Harrison-Bernard L. M., Imig J. D. et al. Renal responses to AT1 receptor blockade. Am. J. Hypertens. 2000; 13: 45S-54S.Murphy T. J., Alexander R. W., Griendling K. K. et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-235.Sasaki K., Yamamo Y., Bardham S. et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin type-1 receptor. Nature 1991; 351: 230-232.Berk B. C., Corson M. A. Angiotensin II signal transduction in vascular smooth muscle. Role of tyrosine kinases. Circ. Res. 1997; 80: 607-616.Mukoyama M., Nakajima M., Horiuchi M. et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993; 268: 24539-24542.Zhuo J., Moeller I., Jenkins T. et al. Mapping tissue angiotensin-converting enzyme an angiotensin AT1, AT2 and AT4 receptors. J. Hypertens. 1998; 16: 2027-2037.Matsusaka T., Ichikawa I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 1997; 59: 395-412.Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol. Dial. Transplant. 1999; 14 (suppl. 1): 42-44.Томилина Н. А., Багдасарян А. Р. Механизмы нефросклероза и фармакологическая ингибиция внутри почечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата. (Обзор литературы). Нефрол. и диализ 2004; 6 (3): 17-25.Klahr S., Morrissey J. J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. 2000; 56 (suppl. 75): 7-14.Wolf G. The renin-angiotensin system and progression of renal disease. In: Wolf G., ed. Contributions to nephrology. 2001.Wenxia Chai, Danser A. H. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn-Schmiedeberg's Arch. Pharmacol. 2006; 374 (3): 153-162.Silvestre J. S., Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 1998; 273: 4883-4891.Gomez-Sanchez C. E., Zhou M. Y., Cozza E. N. et al Aldosterone biosynthesis in the rat brain. Endocrinology 1997; 138: 3369-3373.Takeda Y., Miyamori I., Yoneda T. et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995; 25: 170-173.Takeda Y., Miyamori I., Inaba S. et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29: 45-48.Mortensen R. M., Williams G. H. Aldosterone action. In: DeGroot L. J., Jameson J. L., eds. Endocrinology. 4-th ed. Philadelphia: WB Saunders; 2001. 1783-1789.Bartter F. C., Duncan L. E. Jr., Liddle G. W. The effect of changes in body sodium on extracellular fluid volume and aldosterone and sodium excretion by normal and edematous man. Am. J. Med. 1956; 35 (11): 1299-1305.Schmidt B. M. W., Montealegre A., Janson C. P. et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J. Endocrinol. 1999; 84: 3528-335.Braley L. M., Menachery A. I., Rystedt L., Williams G. H. Sodium-mediated modulation of aldosterone secretion: impact of converting enzyme inhibition on rat glomerulosa cell response to angiotensin II. Endocrinology 1989; 125: 1310-1315.Delcayre C., Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 2002; 34: 1577-1584.Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog Hypertension 1994; 24: 571-575.Abraham G. E., ed. Handbook of radioimmunoassay. New York: Marcel Dekker, Inc.; 1977. 511-591.Deinum J., Derkx F. H., Schalekamp M. A. Improved immunoradiometric assay for plasma renin. Clin. Chem. 1999; 45: 847-854.Ulmer P. S., Meikle A. W. Sample requirements for plasma renin activity and immunoreactive renin. Clin. Chem. 2000; 46 (9): 1442-1444.Sealey J. E. Plasma renin activity and plasma prorenin assays. Clin. Chem. 1991; 37 (10, pt 2): 1811-1819.Scammell A. M., Diver M. J. Plasma aldosterone and renin activity. Arch. Dis. Child. 1989; 64 (1): 139-141.Muller F. B., Sealey J. E., Case D. B. et al. The captopril test for identifying renovascular disease in hypertensive patients. Am. J. Med. 1986; 80 (4): 633-644.Столин А. Р. Роль ядерной медицины в дифференциальной диагностике и прогнозе артериальной гипертензии. Новости лучевой диагн. 2002; 1-2: 14-18.Imanishi M., Ohta M., Kwamura M. et al. Aspirin test for differentiation of unilateral renovascular hypertension from hyperreninemic essential hypertension. Am. J. Hypertens. 1991; 4 (9): 761-768.Campbell D. J. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51 (1): 15-18.Simon D., Hartmann D. J., Badouaille G. et al. Two-site direct immunoassay specific for active renin. Clin. Chem. 1992; 38: 1959-1962.Derkx F. H., de Bruin R. J., van Gool J. M. et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin. Chem. 1996; 42: 1051-1063.Hartman D., Sagnella G. A., Chesters C. A., MacGregor G. A. Direct renin assay and plasma renin activity assay compared. Clin. Chem. 2004; 50: 2159-2161.René A., de Bruin P., Bouhuizen A. et al. Validation of a new automated renin assay. Clin. Chem. 2004; 50: 2111-2116.Miller M. A., Sagnella G. A., MacGregor G. A. Extraction method and nonextracted kit method compared for measuring plasma aldosterone. Clin. Chem. 1997; 43: 1995-1997.Stabler T. V., Siegel A. L. Chemiluminescence immunoassay of aldosterone in serum. Clin. Chem. 1991; 1 (11): 1987-1989.Manolopoulou J., Bielohuby M., Caton S. J. et al. A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum. J. Endocrinol. 2008; 196: 215-224.Kasahara Y., Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin. Chem. 1981; 27: 1922-1925.